Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.

Original languageEnglish
Pages (from-to)455-464
Number of pages10
JournalGastroenterologie Clinique et Biologique
Volume35
Issue number6-7
DOIs
Publication statusPublished - 2011

Fingerprint

Chronic Hepatitis
Interferons
Hepatocellular Carcinoma
Chronic Hepatitis B
Chronic Hepatitis C
Hepatitis B e Antigens
Therapeutics
Epidemiologic Studies
Randomized Controlled Trials
Prospective Studies
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{d612136347694bf5b81595cbf4028f36,
title = "Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?",
abstract = "Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.",
author = "Elena Vezali and Alessio Aghemo and Pietro Lampertico and Massimo Colombo",
year = "2011",
doi = "10.1016/j.clinre.2011.02.008",
language = "English",
volume = "35",
pages = "455--464",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "6-7",

}

TY - JOUR

T1 - Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

AU - Vezali, Elena

AU - Aghemo, Alessio

AU - Lampertico, Pietro

AU - Colombo, Massimo

PY - 2011

Y1 - 2011

N2 - Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.

AB - Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.

UR - http://www.scopus.com/inward/record.url?scp=80052309181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052309181&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2011.02.008

DO - 10.1016/j.clinre.2011.02.008

M3 - Article

C2 - 21435968

AN - SCOPUS:80052309181

VL - 35

SP - 455

EP - 464

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 6-7

ER -